MCID: GST049
MIFTS: 58

Gastrointestinal System Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Cancer

MalaCards integrated aliases for Gastrointestinal System Cancer:

Name: Gastrointestinal System Cancer 12 15
Digestive System Neoplasms 44 73
Gastrointestinal Neoplasms 44 73
Malignant Neoplasm of Gastrointestinal Tract 73
Neoplasm of the Gastrointestinal Tract 29
Gastrointestinal Tract Cancer 12
Cancer of Digestive System 73
Digestive System Cancer 12
Gi Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3119
ICD10 33 C26.9
ICD9CM 35 239.0
NCIt 50 C3052 C4890
SNOMED-CT 68 93811007

Summaries for Gastrointestinal System Cancer

Disease Ontology : 12 An organ system cancer located in gastrointestinal tract that is manifested in organs of the gastrointestinal system.

MalaCards based summary : Gastrointestinal System Cancer, also known as digestive system neoplasms, is related to gastrointestinal stromal tumor and oral cavity cancer, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal System Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs GastroMARK and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Gastrointestinal System Cancer

Diseases in the Gastrointestinal System Cancer family:

Gastrointestinal System Benign Neoplasm

Diseases related to Gastrointestinal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 32.1 AKT1 CCND1 EGFR HOTAIR KIT KRAS
2 oral cavity cancer 32.0 CDH1 EGFR TLR9 TP53 VEGFA
3 pharynx cancer 31.9 AKT1 CCND1 CDH1 CTNNB1 EGFR KIT
4 esophageal cancer 31.8 AKT1 CCND1 CDH1 CTNNB1 EGFR H19
5 gastric cancer 31.8 AFP AKT1 BANCR CCND1 CDH1 CTNNB1
6 familial adenomatous polyposis 30.1 CCND1 CDH1 CTNNB1 KRAS MLH1 TP53
7 pancreatic cancer 30.1 AKT1 CCND1 CDH1 CTNNB1 EGFR H19
8 squamous cell carcinoma 30.0 AKT1 CCND1 CDH1 CTNNB1 EGFR H19
9 lung cancer 29.9 AKT1 BANCR CCND1 CDH1 EGFR H19
10 plexosarcoma 11.1
11 gastrointestinal neuroendocrine tumor 11.0
12 gastrointestinal carcinoma 11.0
13 esophagus squamous cell carcinoma 10.5 BANCR HOTAIR
14 urachal adenocarcinoma 10.5 AFP KRAS
15 apocrine adenoma 10.5 HRAS KRAS
16 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
17 cerebral convexity meningioma 10.5 CDH1 TP53
18 wilms tumor 2 10.5 H19 VEGFA
19 brain ependymoma 10.5 EGFR TP53
20 esophageal adenosquamous carcinoma 10.5 CDH1 WWOX
21 thymoma, familial 10.5 HRAS KIT
22 pancreatic ductal adenocarcinoma 10.5 H19 HOTAIR MALAT1
23 mixed germ cell tumor 10.5 AFP KIT
24 malignant anus melanoma 10.5 ADAM17 KIT
25 small intestine leiomyosarcoma 10.5 ADAM17 KIT
26 small intestinal sarcoma 10.5 ADAM17 KIT
27 leukemia, chronic lymphocytic 2 10.5 HRAS KRAS TP53
28 germ cell cancer 10.4 AFP H19 KIT
29 anaplastic thyroid cancer 10.4 CDH1 CTNNB1 TP53
30 ovarian serous cystadenocarcinoma 10.4 AKT1 HRAS TP53
31 renal cell carcinoma, papillary, 1 10.4 HRAS KIT TP53
32 li-fraumeni syndrome 10.4 EGFR MLH1 TP53
33 sarcoma, synovial 10.4 CDH1 CTNNB1 KIT
34 small cell carcinoma 10.4 EGFR KIT TP53
35 familial colorectal cancer 10.4 CDH1 MLH1 TP53
36 malignant peripheral nerve sheath tumor 10.4 EGFR KIT TP53
37 grade iii astrocytoma 10.4 EGFR TP53 VEGFA
38 inflammatory myofibroblastic tumor 10.4 CCND1 KIT TP53
39 leukemia, chronic myeloid 10.4 H19 HOTAIR HRAS KIT
40 ovarian epithelial cancer 10.4 H19 HOTAIR MALAT1
41 muscular disease 10.4 AKT1 KIT TLR9 TP53
42 lymphoma, non-hodgkin, familial 10.4 CCND1 KMT2D TLR9 TP53
43 rare adenocarcinoma of the breast 10.4 AKT1 KRAS TP53
44 rheumatoid arthritis 10.4 ADAM17 H19 HOTAIR MALAT1 VEGFA
45 neonatal inflammatory skin and bowel disease 10.4 ADAM17 EGFR
46 paronychia 10.4 EGFR HRAS KRAS
47 nasal cavity adenocarcinoma 10.4 HRAS KRAS TP53
48 mature teratoma 10.4 AFP KRAS TP53
49 tongue disease 10.4 CDH1 CTNNB1 TLR9 TP53
50 aggressive digital papillary adenocarcinoma 10.4 HRAS KIT KRAS

Comorbidity relations with Gastrointestinal System Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Cholestasis Deficiency Anemia
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Gastrointestinal System Cancer:



Diseases related to Gastrointestinal System Cancer

Symptoms & Phenotypes for Gastrointestinal System Cancer

UMLS symptoms related to Gastrointestinal System Cancer:


signs and symptoms, digestive

GenomeRNAi Phenotypes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.29 EGFR HRAS KRAS
2 Decreased viability GR00106-A-0 10.29 KRAS
3 Decreased viability GR00221-A-1 10.29 AKT1 CDH1 EGFR HRAS KIT KRAS
4 Decreased viability GR00221-A-2 10.29 AKT1 HRAS KRAS
5 Decreased viability GR00221-A-3 10.29 AKT1 HRAS
6 Decreased viability GR00221-A-4 10.29 AKT1 EGFR
7 Decreased viability GR00301-A 10.29 CDH1 KIT KRAS
8 Decreased viability GR00381-A-1 10.29 KRAS
9 Decreased viability GR00402-S-2 10.29 AKT1 CDH1 EGFR HRAS KIT KRAS
10 Decreased cell migration GR00055-A-1 9.73 ADAM17 AKT1 CTNNB1 EGFR HRAS KRAS
11 Increased cell migration GR00055-A-3 9.35 ADAM17 CTNNB1 EGFR HRAS KRAS
12 Reduced mammosphere formation GR00396-S 9.28 ADAM17 AFP CCND1 CDH1 EGFR H19

MGI Mouse Phenotypes related to Gastrointestinal System Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
2 homeostasis/metabolism MP:0005376 10.47 ADAM17 AFP AKT1 CCND1 CDH1 CTNNB1
3 endocrine/exocrine gland MP:0005379 10.44 ADAM17 AFP AKT1 CCND1 CDH1 CTNNB1
4 cardiovascular system MP:0005385 10.41 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
5 mortality/aging MP:0010768 10.41 ADAM17 AFP AKT1 CCND1 CDH1 CTNNB1
6 growth/size/body region MP:0005378 10.4 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
7 immune system MP:0005387 10.4 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
8 digestive/alimentary MP:0005381 10.39 ADAM17 CCND1 CDH1 CTNNB1 EGFR HRAS
9 hematopoietic system MP:0005397 10.39 ADAM17 AKT1 CCND1 CTNNB1 EGFR KIT
10 integument MP:0010771 10.33 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
11 neoplasm MP:0002006 10.32 AFP AKT1 CCND1 CDH1 CTNNB1 EGFR
12 embryo MP:0005380 10.3 ADAM17 AKT1 CDH1 CTNNB1 EGFR KIT
13 craniofacial MP:0005382 10.27 CCND1 CTNNB1 EGFR HRAS KIT KMT2D
14 nervous system MP:0003631 10.23 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
15 liver/biliary system MP:0005370 10.18 AFP AKT1 CTNNB1 EGFR KIT KRAS
16 muscle MP:0005369 10.15 ADAM17 AKT1 CTNNB1 EGFR KIT KMT2D
17 normal MP:0002873 10.14 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
18 no phenotypic analysis MP:0003012 10.09 CDH1 CTNNB1 EGFR HRAS KIT KRAS
19 limbs/digits/tail MP:0005371 10.08 ADAM17 CTNNB1 EGFR KIT KRAS TP53
20 reproductive system MP:0005389 10.07 ADAM17 AFP AKT1 CCND1 CDH1 CTNNB1
21 hearing/vestibular/ear MP:0005377 10.06 CTNNB1 EGFR KIT KMT2D KRAS TP53
22 respiratory system MP:0005388 9.93 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
23 renal/urinary system MP:0005367 9.92 CTNNB1 EGFR HRAS KIT KRAS TLR9
24 pigmentation MP:0001186 9.85 ADAM17 CTNNB1 EGFR KIT KRAS TP53
25 skeleton MP:0005390 9.73 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
26 vision/eye MP:0005391 9.28 ADAM17 CCND1 CTNNB1 EGFR KIT KRAS

Drugs & Therapeutics for Gastrointestinal System Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
GastroMARK 18 FERUMOXSIL Advanced Magnetics May 1996
2
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
3
SecreFlo 18 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
4
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
5
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 342)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
Parecoxib Approved Phase 4 198470-84-7
4
Celecoxib Approved, Investigational Phase 4,Phase 1 169590-42-5 2662
5
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Zinc Approved, Investigational Phase 4 7440-66-6
8
Insulin Glargine Approved Phase 4 160337-95-1
9
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
10
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
11
Enoxaparin Approved Phase 4 9005-49-6 772
12
Clarithromycin Approved Phase 4 81103-11-9 84029
13
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
14
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
15
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 1177-87-3
18
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
19 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1
22 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 insulin Phase 4
24 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 1
25 Analgesics, Opioid Phase 4,Not Applicable
26 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
27 Narcotics Phase 4,Not Applicable
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Not Applicable
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 1
32 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
33 Insulin, Globin Zinc Phase 4
34 Omega 3 Fatty Acid Phase 4,Phase 3,Phase 2,Not Applicable
35 Vitamins Phase 4,Phase 2,Phase 1,Not Applicable
36 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Cardiotonic Agents Phase 4
38 Bufanolides Phase 4
39 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable
40 Anticoagulants Phase 4,Phase 1,Not Applicable
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Neurotransmitter Agents Phase 4,Phase 3,Not Applicable,Early Phase 1
45 Mydriatics Phase 4,Not Applicable
46 Anesthetics Phase 4,Not Applicable
47 Antiemetics Phase 4,Phase 3,Phase 1,Not Applicable
48 Autonomic Agents Phase 4,Phase 3,Phase 1,Not Applicable
49 Neuromuscular Blocking Agents Phase 4
50 Neuromuscular Nondepolarizing Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 419)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
3 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
4 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Unknown status NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
5 Nutritional Supplementation in Patients With no Signs of Malnutrition Unknown status NCT01894828 Phase 4
6 Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
7 The Laparotomy Study Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
8 Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) Completed NCT02216799 Phase 4 Glargine Insulin;Regular insulin
9 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
10 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
11 Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® Recruiting NCT02444572 Phase 4 Enoxaparin 4000 IU
12 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Recruiting NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
13 Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) Recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
14 ASCEND: A Study of Cardiovascular Events iN Diabetes Active, not recruiting NCT00135226 Phase 4 aspirin;Omega-3-acid Ethyl Esters;Placebo Aspirin;Placebo omega-3-Ethyl Esters
15 HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery Enrolling by invitation NCT03642093 Phase 4
16 Aliskiren Study of Safety and Efficacy in Senior Hypertensives Withdrawn NCT01922141 Phase 4 Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
17 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
18 Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer Unknown status NCT00209742 Phase 3 UFT;USEL/Leucovorin;Krestin
19 Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial Unknown status NCT00164892 Phase 3 Oral Vioxx (Rofecoxib)
20 Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial Unknown status NCT00165048 Phase 3 Vioxx (Rofecoxib)
21 Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers Unknown status NCT02161991 Phase 3 Aprepitant;placebo
22 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
23 Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer Completed NCT02664974 Phase 3
24 Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment Completed NCT01423799 Phase 3
25 Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting Completed NCT00971399 Phase 3 ramosetron;ondansetron
26 Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery Completed NCT00798447 Phase 3 MLF 541;Lipofundin MCT
27 Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects Completed NCT00455247 Phase 3 Glutamine
28 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed NCT00513357 Phase 3 Melatonin;Placebo
29 Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet Completed NCT01775449 Phase 3
30 Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma Completed NCT01829178 Phase 2, Phase 3 Silymarin;Placebo;chemotherapy
31 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis Completed NCT00052962 Phase 3
32 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
33 Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients Completed NCT01523431 Phase 2, Phase 3 Irinotecan Injection [Camptosar];5-fluorouracil;Leucovorin
34 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
35 Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer Recruiting NCT02956876 Phase 3 standard chemotherapy for colorectal cancer
36 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
37 SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Recruiting NCT03448549 Phase 3 Oxaliplatin;Tegafur,gimeracil and oteracil potassium;Xeloda
38 Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) Recruiting NCT03199989 Phase 3 CapeOX(Capecitabine+Oxaliplatin)
39 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
40 Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index Not yet recruiting NCT02576080 Phase 3 Imatinib
41 Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer Not yet recruiting NCT03362177 Phase 3
42 IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer Suspended NCT00316745 Phase 3 Campto, Topotesin;TS-1;L-Plat;Isovorin;5-FU
43 Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery Terminated NCT01023412 Phase 3
44 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
45 A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients Terminated NCT00254436 Phase 3 Procrit (epoetin alfa)
46 Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients Terminated NCT00516269 Phase 3 Methylphenidate;Placebo
47 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
48 Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer Unknown status NCT01608646 Phase 2 S-1 plus oxaliplatin
49 Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer Unknown status NCT00209651 Phase 2 Campto, Topotesin;TS-1
50 Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status NCT02349958 Phase 2

Search NIH Clinical Center for Gastrointestinal System Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: digestive system neoplasms

Genetic Tests for Gastrointestinal System Cancer

Genetic tests related to Gastrointestinal System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Gastrointestinal Tract 29

Anatomical Context for Gastrointestinal System Cancer

MalaCards organs/tissues related to Gastrointestinal System Cancer:

41
Testes, Colon, Liver, Lung, Tongue, Pancreas, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Cancer:

19
Gastrointestinal Tract

Publications for Gastrointestinal System Cancer

Articles related to Gastrointestinal System Cancer:

# Title Authors Year
1
The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. ( 29429533 )
2018
2
Solute carrier transporters: potential targets for digestive system neoplasms. ( 29416375 )
2018
3
The effect of intraoperative hypothermia upon blood transfusion needs and length of stay among gastrointestinal system cancer surgery. ( 28417506 )
2017
4
Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). ( 15587331 )
2004
5
Streptococcus bovis bacteremia and digestive system neoplasms. ( 3194717 )
1988

Variations for Gastrointestinal System Cancer

Expression for Gastrointestinal System Cancer

Search GEO for disease gene expression data for Gastrointestinal System Cancer.

Pathways for Gastrointestinal System Cancer

Pathways related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
2
Show member pathways
14.15 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
3
Show member pathways
13.97 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
4
Show member pathways
13.64 AKT1 CDH1 EGFR HRAS KIT KRAS
5
Show member pathways
13.6 AKT1 CTNNB1 EGFR HRAS KIT KMT2D
6
Show member pathways
13.52 AKT1 CCND1 EGFR HRAS KIT KRAS
7
Show member pathways
13.46 ADAM17 AKT1 CCND1 EGFR HRAS KIT
8
Show member pathways
13.4 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
9
Show member pathways
13.38 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
10
Show member pathways
13.31 ADAM17 AKT1 CCND1 EGFR HRAS KRAS
11
Show member pathways
13.17 AKT1 EGFR HRAS KIT KRAS TP53
12
Show member pathways
13.15 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
13
Show member pathways
13.13 AKT1 CTNNB1 EGFR HRAS KRAS VEGFA
14
Show member pathways
13.12 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
15
Show member pathways
13.07 AKT1 CTNNB1 EGFR HRAS KRAS TP53
16
Show member pathways
13.05 AKT1 CCND1 CTNNB1 EGFR HRAS KIT
17
Show member pathways
13.02 AKT1 EGFR HRAS KIT KRAS TP53
18
Show member pathways
13.01 ADAM17 AKT1 EGFR HRAS KRAS VEGFA
19
Show member pathways
13.01 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
20 12.86 AKT1 EGFR HRAS KIT KRAS TP53
21
Show member pathways
12.85 AKT1 CCND1 CDH1 EGFR HRAS KRAS
22
Show member pathways
12.83 AKT1 CCND1 EGFR HRAS KRAS
23
Show member pathways
12.83 AKT1 EGFR HRAS KIT KRAS TP53
24
Show member pathways
12.82 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
25
Show member pathways
12.79 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
26
Show member pathways
12.78 AKT1 EGFR HRAS KRAS TP53
27
Show member pathways
12.75 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
28
Show member pathways
12.74 ADAM17 AKT1 CCND1 CTNNB1 HRAS
29
Show member pathways
12.73 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
30
Show member pathways
12.7 AKT1 CTNNB1 EGFR HRAS KRAS TP53
31
Show member pathways
12.64 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
32 12.63 CCND1 EGFR HRAS KRAS TP53 VEGFA
33
Show member pathways
12.61 AKT1 EGFR HRAS KRAS TP53
34
Show member pathways
12.58 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
35
Show member pathways
12.56 AKT1 CCND1 EGFR HRAS KRAS TP53
36 12.54 AKT1 CCND1 CDH1 CTNNB1 TP53
37
Show member pathways
12.54 CCND1 CTNNB1 EGFR HRAS KRAS
38
Show member pathways
12.53 AKT1 EGFR HRAS KRAS TLR9 VEGFA
39
Show member pathways
12.53 AKT1 CTNNB1 EGFR HRAS KRAS TP53
40
Show member pathways
12.52 AKT1 CCND1 HRAS TP53
41
Show member pathways
12.52 AKT1 CCND1 EGFR HRAS KRAS
42
Show member pathways
12.52 AKT1 EGFR HRAS KIT KRAS
43
Show member pathways
12.52 AKT1 CTNNB1 HRAS KRAS VEGFA
44
Show member pathways
12.51 CDH1 CTNNB1 EGFR HRAS KIT KRAS
45 12.51 AKT1 CCND1 CTNNB1 HRAS KRAS TP53
46
Show member pathways
12.49 AKT1 CCND1 HRAS TP53
47
Show member pathways
12.49 CCND1 CTNNB1 EGFR HRAS KIT KMT2D
48
Show member pathways
12.43 AKT1 CCND1 CTNNB1 HRAS
49
Show member pathways
12.42 AKT1 CCND1 EGFR HRAS
50
Show member pathways
12.42 AKT1 EGFR HRAS KRAS

GO Terms for Gastrointestinal System Cancer

Cellular components related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
2 cell-cell junction GO:0005911 8.92 ADAM17 AKT1 CTNNB1 KIT
3 cytoplasm GO:0005737 10 ADAM17 AFP AKT1 CCND1 CDH1 CTNNB1

Biological processes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 AKT1 CTNNB1 EGFR KIT TP53 VEGFA
2 cell proliferation GO:0008283 9.96 AKT1 CTNNB1 EGFR HRAS TP53
3 negative regulation of gene expression GO:0010629 9.95 AKT1 CTNNB1 HRAS VEGFA
4 cytokine-mediated signaling pathway GO:0019221 9.93 AKT1 CCND1 KIT KRAS TP53 VEGFA
5 MAPK cascade GO:0000165 9.92 EGFR HRAS KIT KRAS
6 positive regulation of cell migration GO:0030335 9.88 ADAM17 EGFR HRAS KIT VEGFA
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 AKT1 EGFR VEGFA
8 liver development GO:0001889 9.81 CCND1 EGFR KRAS
9 positive regulation of cell growth GO:0030307 9.8 ADAM17 AKT1 EGFR
10 cellular response to hypoxia GO:0071456 9.8 AKT1 MALAT1 TP53 VEGFA
11 positive regulation of MAPK cascade GO:0043410 9.8 CTNNB1 EGFR HRAS KIT TLR9
12 Ras protein signal transduction GO:0007265 9.78 HRAS KRAS TP53
13 positive regulation of epithelial cell proliferation GO:0050679 9.76 EGFR HRAS VEGFA
14 positive regulation of gene expression GO:0010628 9.76 AKT1 CTNNB1 HRAS KIT KRAS TLR9
15 cellular response to growth factor stimulus GO:0071363 9.74 AKT1 CTNNB1 EGFR
16 epidermal growth factor receptor signaling pathway GO:0007173 9.72 ADAM17 AKT1 EGFR
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.71 ADAM17 AKT1 VEGFA
18 positive regulation of MAP kinase activity GO:0043406 9.65 EGFR HRAS KIT KRAS VEGFA
19 tongue development GO:0043586 9.64 EGFR KIT
20 positive regulation of cellular component movement GO:0051272 9.62 ADAM17 VEGFA
21 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 EGFR TP53
22 entry of bacterium into host cell GO:0035635 9.6 CDH1 CTNNB1
23 mitotic G1 DNA damage checkpoint GO:0031571 9.59 CCND1 TP53
24 response to isolation stress GO:0035900 9.58 HRAS KRAS
25 obsolete positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.54 ADAM17 AKT1 EGFR
26 cellular response to indole-3-methanol GO:0071681 9.52 CDH1 CTNNB1
27 response to UV-A GO:0070141 9.5 AKT1 CCND1 EGFR
28 positive regulation of protein phosphorylation GO:0001934 9.5 ADAM17 AKT1 CCND1 EGFR HRAS KRAS
29 positive regulation of cell proliferation GO:0008284 9.32 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
30 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 AKT1 CTNNB1 EGFR HRAS KMT2D TLR9

Molecular functions related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 AKT1 CCND1 CTNNB1 EGFR TP53
2 protein phosphatase binding GO:0019903 9.5 CTNNB1 EGFR TP53
3 nucleotide binding GO:0000166 9.35 AKT1 EGFR HRAS KIT KRAS
4 nitric-oxide synthase regulator activity GO:0030235 9.26 AKT1 EGFR
5 enzyme binding GO:0019899 9.17 AKT1 CCND1 CTNNB1 EGFR MLH1 TP53

Sources for Gastrointestinal System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....